PLA2G4A is overexpressed in different solid cancers such as hepatocellular carcinoma (Fu et al., 2017), prostate cancer (Patel et al., 2008), breast cancer (Chen et al., 2017), cervical cancer (Xu et al., 2019), as well as malignant hematologic diseases, such as AML (acute myeloid leukemia) (Runarsson et al., 2007; Bai et al., 2020; Zhang et al., 2022) In multiple myeloma patients, expression of the PLA2G4A was higher compared to healthy individuals and high gene expression of PLA2G4A is associated with adverse outcomes (Mahammad et al., 2021). Here, PLA2G4A is linked to prostate carcinoma.